Medina

Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with lichen planopilaris, a condition affecting the scalp. This Phase 23 trial aims to understand how well this medication works compared to a placebo in treating active and symptomatic lichen planopilaris. The study is sponsored by Priovant Therapeutics, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants are randomly assigned to receive either oral brepocitinib or a placebo. The study is conducted in parallel groups, with neither the participants nor the researchers knowing who receives the active drug or placebo. The treatment period lasts 24 weeks, during which the participants take the assigned oral medication. The main goal is to measure improvement in the Investigator Global Assessment IGA score by Week 24. Throughout the study, participants will be regularly monitored for safety and symptom changes. Researchers will assess the proportion of participants who achieve significant improvement in their IGA scores at Week 24 and track changes in symptom severity using a numerical rating scale. The total study duration extends until July 2029, allowing for thorough evaluation of treatment effects and safety over time.

Dry eye disease DED is a common condition that affects both working-age adults and the elderly, causing symptoms like dryness and burning, and signs such as decreased tear production or increased tear evaporation. Diagnosing and treating DED can be challenging because symptoms and signs do not always match. This research aims to study a new treatment called Acoltremon 0.003% TRYPTYR, recently approved by the FDA, to see if it can improve the quality of life and work ability of people suffering from DED by stimulating tear production through activating specific nerve receptors. Participants who qualify will receive TRYPTYR during the 1-month study, which includes three visits. TRYPTYR acts as a TRPM8 receptor agonist that stimulates cold thermoreceptors on the eyes nerves to increase tear production. The study focuses on assessing the effect of this medication on patients experiencing dry eye symptoms, with dosing and administration details provided during the visits. During the study, adults aged 18 to 75 years with diagnosed DED lasting at least six months and currently symptomatic will be assessed through visual analog scales, tear tests, and quality of life questionnaires related to work. Researchers will monitor changes in work-related quality of life scores at 14 and 28 days. Participants will also undergo eye exams, vision tests, and symptom assessments to track safety and treatment effects throughout the study.

Researchers are evaluating how Qlosi14 pilocarpine HCL ophthalmic solution 0.4% affects the quality of life in people with presbyopia, a condition causing near vision problems. This Phase 4, multi-center study aims to measure improvements in near vision symptoms using validated questionnaires such as the Near Activity Visual Questionnaire-Presbyopia NAVQ-P and the Visual Quality of Life with Time Survey VisQualT. The study focuses on participants aged 45 to 64 who experience near vision blur despite having corrected distance vision. Participants will use Qlosi twice daily in both eyes, while only using reading glasses for urgent tasks. At the screening visit, all subjects will receive distance spectacles without near correction and have their baseline visual acuity and survey data collected. After confirming good distance vision with the spectacles, participants will start the study treatment. The treatment period lasts four weeks, after which participants return for an evaluation visit to assess changes in vision and quality of life. During the study, researchers will collect visual acuity data, responses to questionnaires, and text message surveys at various time points up to one month. Eye exams including slit-lamp biomicroscopy and indirect ophthalmoscopy will be performed at screening. Participants will be monitored for any changes or side effects, and after completing the evaluation visit, they will be compensated and exited from the study. The total participation time spans approximately 4 to 6 weeks from screening to study exit.

Researchers are evaluating the safety and effectiveness of VDPHL01, an investigational oral drug, in female subjects with Androgenetic Alopecia AGA, a genetic condition causing hair loss due to an excessive response to hormones called androgens. This Phase 3, multi-center, double-blind study aims to better understand treatment outcomes for women aged 18 to 65 with mild to moderate AGA. The study is sponsored by Veradermics, Inc. and includes about 13 months of participation with 11 scheduled visits. Participants will be randomly assigned to one of several groups receiving different regimens of VDPHL01 or placebo. Some groups take VDPHL01 twice daily BID for the entire 12 months, while others begin with placebo or a combination of VDPHL01 once daily QD and placebo before switching treatments after 6 months. The study maintains a double-blind design, meaning neither participants nor researchers know who receives the active drug or placebo during the first 6 months. Throughout the study, participants will attend visits for screening, baseline assessment, and follow-ups at weeks 2, months 1, 2, 4, 6, 8, 10, 12, and 13. Researchers will evaluate hair counts in target areas at 6 months and participants own assessment of treatment benefit. Participants agree to maintain consistent hair length, style, and color, and will have a small tattoo placed on their scalp for photographic monitoring. Safety and treatment effects will be carefully monitored during the study period.